Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mesna inactivates platinum agents in vitro

J E Wolff1, R M Egeler, R Anderson

  • 1Alberta Children's Hospital, Calgary, Canada. johannes.wolff@crha-health.ab.ca

Anticancer Research
|January 19, 1999
PubMed
Summary

Mesna (chemical compound) can interfere with platinum-based chemotherapy drugs like cisplatin and carboplatin. This study found mesna protected cancer cells from platinum agents, suggesting careful dosing is needed in clinical settings.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Heaps of moles? - Mediating macroscopic and microscopic measurement of chemical substances.

Studies in history and philosophy of science·2020
Same author

Why eliminativism?

Studies in history and philosophy of science·2019
Same author

Whole body measurement of C, N and O using 14 MeV neutrons and the associated particle time-of-flight technique.

Asia Pacific journal of clinical nutrition·2014
Same author

Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours.

European journal of cancer (Oxford, England : 1990)·2006
Same author

Expression of p33ING1 mRNA and chemosensitivity in brain tumor cells.

Anticancer research·2003
Same author

Choroid plexus tumours.

British journal of cancer·2002

Area of Science:

  • Oncology
  • Pharmacology
  • Cancer Cell Biology

Background:

  • Platinum-based chemotherapy agents are commonly used in combination with ifosfamide for cancer treatment.
  • Mesna is administered to mitigate ifosfamide's side effects but may interact with platinum agents.

Purpose of the Study:

  • To investigate the potential interaction between mesna and platinum agents (cisplatin, carboplatin) in malignant glioma cells.
  • To assess the impact of mesna on the cytotoxicity of platinum agents.

Main Methods:

  • Malignant glioma cell lines (U87, C6, T98G, U251) were exposed to cisplatin, carboplatin, and mesna.
  • Cell viability was assessed using direct cell counting and MTT assays.

Main Results:

Related Experiment Videos

  • Mesna demonstrated cell-line specific effects, impacting cell numbers in C6 and T98G cells.
  • Mesna protected all tested glioma cell lines from the cytotoxic effects of both cisplatin and carboplatin.
  • Higher concentrations of platinum agents were required to achieve 50% cell death in the presence of mesna.

    • Conclusions:

    • Mesna can reduce the efficacy of platinum-based chemotherapy agents.
    • Clinical protocols should precisely define the administration schedules for mesna and platinum agents to optimize treatment outcomes.